STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries

The Biotechnology Innovation Organization, or BIO, joined two California-based biotech trade groups in challenging GLOBE. They filed a complaint Friday in the U.S. District Court for the Northern District of California. The groups represent biotechnology interests affected by Medicare drug-payment policies.

Their complaint says GLOBE exceeds Medicare’s legal authority. They are asking the court to stop the demonstration before it proceeds or expands. The filing targets the model itself, not merely a particular price decision.

The case is now a legal test of how far Medicare can go when designing payment experiments. CMS had not immediately responded to a request for comment. The article does not state whether the court has issued a ruling, so the pilot’s future remains unresolved.

The Global Benchmark for Efficient Drug Pricing demonstration, or GLOBE, is a Medicare payment model. Its stated aim is to align prices for some drugs with prices charged in peer countries. That matters because it would replace a purely domestic pricing approach with one that looks abroad.

The central mechanism is an international benchmark. Medicare would use prices in selected peer countries as a reference when determining payment for drugs covered by the pilot. The article does not identify the drugs, countries, benchmark formula, or size of any reduction.

GLOBE remains contested rather than settled policy. BIO and two California trade groups say the model exceeds Medicare’s statutory authority and seek to halt it. CMS had not commented when the article was published, and no implementation outcome is given.

Tying Medicare prices to peer-country prices means using overseas prices as a reference point for what Medicare pays. “Peer countries” generally means comparable, often high-income nations, although the article does not name them. The approach treats international prices as evidence of a reasonable payment level.

For example, if a drug costs less in several selected countries, a benchmark model could use those prices to guide Medicare’s payment. The exact formula matters. It could compare listed prices, negotiated prices, or an average, but the article does not provide those details. GLOBE’s defining feature is the international reference.

Such a policy could lower Medicare payments for some drugs, depending on the comparison. It could also change how manufacturers plan prices across markets. Here, the approach is only a disputed pilot. BIO argues the agency lacks authority to impose it.

Medicare is one of the largest health programs in the United States. Recent federal estimates put enrollment at roughly 67 million people and total annual spending above $1 trillion. Prescription-drug spending is only one part of that budget, but it still reaches well over $100 billion annually, depending on whether accounting includes premiums, rebates, and different Medicare components.

A limited pilot can matter because a payment rule may affect many prescriptions even if it covers only selected drugs or beneficiaries. If Medicare pays less, federal spending and some patient costs could fall. If prices are already negotiated or discounted, the measured savings could be smaller than the headline benchmark.

The article gives no enrollment, spending, drug, or beneficiary figures for GLOBE. Its importance instead comes from precedent. A court decision could determine whether CMS may test international price benchmarks and could shape future Medicare pricing proposals.

If GLOBE takes effect, Medicare could pay less for some drugs when peer-country prices are lower. Taxpayers could benefit through reduced federal spending, and patients might see lower cost sharing when their payments are linked to Medicare’s price. The size of any benefit would depend on the model’s design and coverage.

Biotech companies could face lower prices and revenue for affected products. They might respond by changing launch prices, research priorities, or market strategies, though the article does not predict any response. Patients could also face uncertainty if manufacturers alter availability or coverage, but the source provides no evidence that this would happen.

If the court blocks GLOBE, the proposed international benchmark would not operate under this model. Medicare’s existing approach would continue unless another policy changed it. The lawsuit could also clarify the legal limits on CMS demonstrations, affecting future drug-pricing experiments.

The groups’ legal position is that Medicare’s authority comes from statutes passed by Congress. An agency may administer the program and conduct authorized demonstrations, but it cannot create a payment system that goes beyond those limits. BIO and the two California trade groups say GLOBE crosses that line.

The complaint specifically asserts that the Global Benchmark for Efficient Drug Pricing demonstration oversteps Medicare’s statutory authority. That argument focuses on power, not merely on whether international benchmarks produce fair or efficient prices. The groups therefore ask the court to halt the model rather than simply revise a price.

The article does not identify the specific statutory language, CMS rule, or legal precedent behind the claim. CMS also did not immediately respond to a request for comment. The court will therefore be central to determining whether the agency can test this international pricing approach.

Medicare is the federal health insurance program mainly serving older adults and certain people with disabilities. It has different parts, including hospital, physician, and prescription-drug coverage. Prescription-drug coverage is commonly delivered through Part D plans, while Medicare sets rules and oversees the program through the Department of Health and Human Services and CMS.

Price-setting authority depends on the drug benefit and the governing law. Congress writes the statute. CMS administers the program, establishes rules, and can conduct demonstrations when Congress has authorized them. Private plans may negotiate with manufacturers or pharmacy networks, but they operate within Medicare’s legal framework.

GLOBE tests that boundary. CMS is attempting to use a demonstration to connect some Medicare drug payments to peer-country prices. BIO argues that the statute does not authorize this step. The article does not identify the precise legal provisions, so the court must evaluate the groups’ claim against CMS’s authority.